175 results on '"Lee, Byron H."'
Search Results
2. Exploring the utility of snRNA-seq in profiling human bladder tissue: A comprehensive comparison with scRNA-seq
3. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
4. Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy
5. Single-cell and spatial mapping Identify cell types and signaling Networks in the human ureter
6. Neighborhood Socioeconomic Disadvantage Associated With Increased 90-Day Mortality Following Radical Cystectomy
7. An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancer
8. Comparison of Oncologic Outcomes Following Open and Robotic-assisted Radical Cystectomy with both Extracorporeal and Intracorporeal Urinary Diversion
9. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology
10. Intracorporeal Urinary Diversion in Robotic Radical Cystectomy
11. Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.
12. DNA Methylation Regulates Alternative Polyadenylation via CTCF and the Cohesin Complex
13. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
14. The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy
15. Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade
16. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma
17. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma
18. Ability of the surgical Apgar score to predict acute kidney injury following radical cystectomy
19. 5mC: what goes on must come off
20. Survival outcomes following radical cystectomy in patients with prior pelvic radiation for prostate cancer: A matched cohort analysis
21. Comparison of renal function after open radical cystectomy, extracorporeal robot assisted radical cystectomy, and intracorporeal robot assisted radical cystectomy
22. Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer
23. Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma
24. Real-Time Robotic Transrectal Ultrasound Navigation During Robotic Radical Prostatectomy: Initial Clinical Experience
25. Diameter-Axial-Polar Nephrometry: Integration and Optimization of R.E.N.A.L. and Centrality Index Scoring Systems
26. Nephrometry Score is Associated with Volume Loss and Functional Recovery After Partial Nephrectomy
27. Functional Recovery After Partial Nephrectomy: Effects of Volume Loss and Ischemic Injury
28. Bilateral Synchronous Sporadic Renal Tumors: Pathologic Concordance and Clinical Implications
29. Utility of Percent Free Prostate-specific Antigen in Repeat Prostate Biopsy
30. Percentage of Free Prostate-specific Antigen: Implications in Modern Extended Scheme Prostate Biopsy
31. Commentary on: “Comprehensive molecular characterization of papillary renal-cell carcinoma.” Cancer Genome Atlas Research Network.: N Engl J Med. 2016 Jan 14;374(2):135–45.
32. Commentary on: “Clonal evolution of chemotherapy-resistant urothelial carcinoma.” Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.: Nat Genet. 2016 Oct 17. http://dx.doi.org/10.1038/ng.3692.
33. Commentary on: “An integrated metabolic atlas of clear cell renal cell carcinoma.” Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, Hsieh JJ.: Cancer Cell. 2016 Jan 11;29(1):104–16.
34. Commentary on: “Comprehensive transcriptional analysis of early-stage urothelial carcinoma.” Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MB, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KE, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L. Cancer Cell. 2016 Jul 11;30(1):27–42
35. Commentary on: “Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.” Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Nature. 2016 May 25;533(7604):547–51.
36. Commentary on: “Inherited DNA-repair gene mutations in men with metastatic prostate cancer.” Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443–53.
37. ONCOLOGIC OUTCOMES OF INTRAVESICAL THERAPY IN THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY
38. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
39. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome
40. Editorial Comment
41. Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1
42. Processing and cryopreservation of human ureter tissues for single-cell and spatial transcriptomics assays
43. AUTHOR REPLY
44. GSTP1 CpG Island Hypermethylation Is Responsible for the Absence of GSTP1 Expression in Human Prostate Cancer Cells
45. EDITORIAL COMMENT
46. PD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN.
47. MP16-08 CHALLENGING THE PARADIGM OF "BCG UNRESPONSIVE" BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT?
48. EDITORIAL COMMENT
49. Editorial Comment
50. Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.